Search company, investor...

Predict your next investment

Eli Lilly and Company company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
lilly.com

Investments

83

Portfolio Exits

26

Funds

1

Partners & Customers

10

Service Providers

3

About Eli Lilly and Company

Eli Lilly and Company is a drug firm that focuses on neuroscience, endocrinology, cancer, and immunology. Its key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, and Humulin for diabetes, and Taltz and Olumiant for immunology. The company was founded in 1876 and is based in Indianapolis, Indiana.

Headquarters Location

Lilly Corporate Center

Indianapolis, Indiana, 46285,

United States

800-545-5979

Want to inform investors similar to Eli Lilly and Company about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Eli Lilly and Company

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Eli Lilly and Company in 4 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

D

Diabetes

1,903 items

M

Medical Devices

3,501 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

B

Biopharma Tech

260 items

Latest Eli Lilly and Company News

Retroperitoneal Liposarcoma Treatment Market Is Booming Worldwide 2023-2028 | Eli Lilly and Company

Jan 27, 2023

| Eli Lilly and Company News Provided By Share This Article Retroperitoneal Liposarcoma Treatment Market Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space BURLINGAME, CA, UNITED STATES, January 26, 2023 / EINPresswire.com / -- Edition 2023: This report studies the Retroperitoneal Liposarcoma Treatment Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Retroperitoneal Liposarcoma Treatment Market analysis segmented by companies, region, type and applications in the report. The report offers valuable insight into the Retroperitoneal Liposarcoma Treatment market progress and approaches related to the Retroperitoneal Liposarcoma Treatment market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment. What’s New for 2023? Global competitiveness and key competitor market share percentages Strong/Active/Niche/Trivial market presence across multiple geographies Online interactive peer-to-peer collaborative bespoke updates To Get More Business Strategies Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1861 Market Overview: Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of the factors leading to the generation of these tumors. Incidence of this disease is equal in men and women, with a slight predominance of men. This tumor has no characteristic symptoms and are usually diagnosed during the advanced stage. List of TOP KEY PLAYERS in Retroperitoneal Liposarcoma Treatment Market Report are: Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories, and Zydus Cadila. The global Retroperitoneal Liposarcoma Treatment market segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Retroperitoneal Liposarcoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2023-2028. Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Direct Buy This Premium Research Report Here Up to 25% OFF@ - https://www.coherentmarketinsights.com/insight/buy-now/1861 Detailed Segmentation: Research objectives: To study and analyze the global Retroperitoneal Liposarcoma Treatment market size by key regions/countries, product type and application, history data from 2018 to 2023, and forecast to 2028. To understand the structure of Retroperitoneal Liposarcoma Treatment market by identifying its various sub segments. Focuses on the key global Retroperitoneal Liposarcoma Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Retroperitoneal Liposarcoma Treatment with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the size of Retroperitoneal Liposarcoma Treatment submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies. Table of Contents: Retroperitoneal Liposarcoma Treatment Market Part 1: Overview of Retroperitoneal Liposarcoma Treatment Market Part 2: Retroperitoneal Liposarcoma Treatment Carts: Global Market Status and Forecast by Regions Part 3: Global Market Status and Forecast by Types Part 4: Global Market Status and Forecast by Downstream Industry Part 5: Market Driving Factor Analysis Part 6: Market Competition Status by Major Manufacturers Part 7: Major Manufacturers Introduction and Market Data Part 8: Upstream and Downstream Market Analysis Part 9: Cost and Gross Margin Analysis Part 10: Marketing Status Analysis Part 11: Market Report Conclusion Part 12: Retroperitoneal Liposarcoma Treatment: Research Methodology and Reference Key questions answered in the report: Which regional market will show the highest and rapid growth? Which are the top five players of the Retroperitoneal Liposarcoma Treatment Market? How will the Retroperitoneal Liposarcoma Treatment Market change in the upcoming six years? Which application and product will take a lion’s share of the Retroperitoneal Liposarcoma Treatment Market? What is the Retroperitoneal Liposarcoma Treatment market drivers and restrictions? What will be the CAGR and size of the Retroperitoneal Liposarcoma Treatment Market throughout the forecast period? Do You Have Specific Requirement? Ask To Our Experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1861 Why Choose Coherent Market Insights? Coherent Market Insights is our BI-enabled platform for narrative storytelling of this market. CMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future. CMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. CMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market. About us: Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Mr. Shah +1 206-701-6702

Eli Lilly and Company Investments

83 Investments

Eli Lilly and Company has made 83 investments. Their latest investment was in PrescriberPoint as part of their Seed on January 1, 2023.

CBI Logo

Eli Lilly and Company Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/31/2023

Seed

PrescriberPoint

Yes

1

12/5/2022

Series A

SonoThera

$60.75M

Yes

10

11/28/2022

Series A - II

Strand Therapeutics

$45M

Yes

12

9/14/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/8/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/31/2023

12/5/2022

11/28/2022

9/14/2022

9/8/2022

Round

Seed

Series A

Series A - II

Series A

Series A

Company

PrescriberPoint

SonoThera

Strand Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$60.75M

$45M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

12

10

10

Eli Lilly and Company Portfolio Exits

26 Portfolio Exits

Eli Lilly and Company has 26 portfolio exits. Their latest portfolio exit was Blacksmith Medicines on January 03, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/3/2023

Merger

$99M

1

12/28/2021

Take Private

$99M

7

5/28/2021

Acquired

$99M

2

3/30/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

2/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/3/2023

12/28/2021

5/28/2021

3/30/2021

2/5/2021

Exit

Merger

Take Private

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

7

2

10

10

Eli Lilly and Company Acquisitions

24 Acquisitions

Eli Lilly and Company acquired 24 companies. Their latest acquisition was Akouos on October 18, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/18/2022

Series B

$99M

$162.58M

Acquired

36

7/14/2021

Seed / Angel

$99M

Acquired

4

1/22/2021

Series B

$99M

$135M

Acq - P2P

10

10/15/2020

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

2/20/2020

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

10/18/2022

7/14/2021

1/22/2021

10/15/2020

2/20/2020

Investment Stage

Series B

Seed / Angel

Series B

Grant

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$162.58M

$135M

$99M

$99M

Note

Acquired

Acquired

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

36

4

10

10

10

Eli Lilly and Company Fund History

1 Fund History

Eli Lilly and Company has 1 fund, including Australia Biotech Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Australia Biotech Fund

Early-Stage Venture Capital

Anticipated

1

Closing Date

Fund

Australia Biotech Fund

Fund Type

Early-Stage Venture Capital

Status

Anticipated

Amount

Sources

1

Eli Lilly and Company Partners & Customers

10 Partners and customers

Eli Lilly and Company has 10 strategic partners and customers. Eli Lilly and Company recently partnered with Be Nimble on January 1, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

1/24/2023

Partner

United States

Be Nimble Foundation, Lilly partner on talent recruitment

Be Nimble , which focuses on creating a diverse and inclusive tech ecosystem , has entered into a partnership with Indianapolis-based Eli Lilly and Co. to help recruit and train candidates .

1

1/18/2023

Partner

China

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

In March 2022 , Lilly and Innovent Biologics , Inc. deepened the strategic partnership in oncology , in which Innovent Biologics , Inc. obtained the sole commercialization rights to import , market , promote , distribute and detail CYRAMZA ® and Selpercatinib , and a right of first negotiation for potential future commercialization of pirtobrutinib in Mainland China .

2

1/17/2023

Licensee

United States

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

Building on its deep and long-standing scientific and commercial experience and insight in the Chinese migraine market , AffaMed Therapeutics views this collaboration with Eli Lilly and Company as a critical opportunity to address the significant unmet need and to improve the quality of life for migraine patients in China .

2

1/16/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

1/9/2023

Licensee

China

Subscribe to see more

Subscribe to see more

10

Date

1/24/2023

1/18/2023

1/17/2023

1/16/2023

1/9/2023

Type

Partner

Partner

Licensee

Partner

Licensee

Business Partner

Country

United States

China

United States

United States

China

News Snippet

Be Nimble Foundation, Lilly partner on talent recruitment

Be Nimble , which focuses on creating a diverse and inclusive tech ecosystem , has entered into a partnership with Indianapolis-based Eli Lilly and Co. to help recruit and train candidates .

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

In March 2022 , Lilly and Innovent Biologics , Inc. deepened the strategic partnership in oncology , in which Innovent Biologics , Inc. obtained the sole commercialization rights to import , market , promote , distribute and detail CYRAMZA ® and Selpercatinib , and a right of first negotiation for potential future commercialization of pirtobrutinib in Mainland China .

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

Building on its deep and long-standing scientific and commercial experience and insight in the Chinese migraine market , AffaMed Therapeutics views this collaboration with Eli Lilly and Company as a critical opportunity to address the significant unmet need and to improve the quality of life for migraine patients in China .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

Eli Lilly and Company Service Providers

4 Service Providers

Eli Lilly and Company has 4 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Other

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Subscribe to see more

Provider Type

Other

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Eli Lilly and Company Team

62 Team Members

Eli Lilly and Company has 62 team members, including current Chief Executive Officer, David Ricks.

Name

Work History

Title

Status

David Ricks

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

David Ricks

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Eli Lilly and Company to Competitors

N
Norstella

Norstella is a group of pharmaceutical solutions providers offering clients tools and expertise to navigate complexities for each step of the drug development life cycle, from pipeline to patient. The company is based in Morrisville, Pennsylvania.

Nview Health Logo
Nview Health

Nview Health delivers online behavioral health solutions for healthcare professionals and research organizations to screen for and monitor mental disorders in children and adults. Its flagship offering, the M.I.N.I. (Mini International Neuropsychiatric Interview), is a cloud-based, HIPAA-compliant solution available on any web-enabled device including mobile tablets and smartphones, which allows screenings and interviews to be administered in the office or at home.

Meru Health Logo
Meru Health

Meru Health is an online medical clinic treating depression and burnout. Meru Health's treatment program combines psychological treatment modules, patient data, and a licensed therapist. Meru Health individualizes the program based on patients' personal information and needs. It was founded in 2015 and is based in San Mateo, California.

Noom Logo
Noom

Noom is a mobile health company that develops behavioral change programs that combine human coaches with personalized content to help people achieve their wellness goals. Users complete a questionnaire, download the Noom app and are paired with a dedicated health coach and customized content that evolves based on their needs.

Floreo Logo
Floreo

Floreo uses VR interactive content to help people with autism spectrum disorder, especially kids and teens, with everything from police interactions to school work. It was founded in 2016 and is based in Washington, DC.

L
Luminary Therapeutics

Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.